本文已被:浏览 17次 下载 7次
Received:January 16, 2024 Published Online:November 20, 2024
Received:January 16, 2024 Published Online:November 20, 2024
中文摘要: 脓毒症是临床常见危重症,具有很高的死亡率。急性呼吸窘迫综合征(ARDS)是一种急性的肺部炎症性损伤疾病,是脓毒症发生发展过程中常见的并发症,可导致脓毒症患者的病死率显著增加。及时诊断和早期干预是改善 ARDS患者预后的关键,但由于疾病的高度异质性,临床诊疗难以实现突破性进展,目前以较为保守的器官功能支持治疗为主,病死率仍居高不下。国际上提倡对脓毒症相关ARDS患者实行精准的个体化治疗,目前已对脓毒症相关ARDS的发病机制取得进步性发现,各种新型治疗手段为改善患者预后带来希望。本文对脓毒症相关ARDS的流行病学、发病机制、新型诊断及治疗干预措施进行综述。
Abstract:Sepsis is a clinically common critical illness with high mortality rate. Acute respiratory distress syndrome (ARDS), an acute inflammatory lung injury disease, is a common complication during the development of sepsis and can lead to a significant increase in the morbidity and mortality of sepsis patients. Timely diagnosis and early intervention are the keys to improving the prognosis of ARDS patients. However, due to the high heterogeneity of the disease, it is difficult to achieve breakthrough progress in clinical diagnosis and treatment. Currently, the main treatment is relatively conservative organ function support, but the mortality rate remains high. The international community advocates precise individualized treatment for sepsis-related ARDS patients, and progress has been made in understanding the pathogenesis of sepsis-related ARDS. Various new treatment methods have brought hope for improving the prognosis of patients. This article summarizes the epidemiology, pathogenesis, new diagnosis and treatment interventions of sepsis-related ARDS.
keywords: Sepsis Acute lung injury Acute respiratory distress syndrome Pathogenesis Endothelial injury Immune dysfunction Cell death Mitochondrial dysfunction Infection Individualized treatment
文章编号: 中图分类号:R631 文献标志码:A
基金项目:
引用文本: